Quelle est la meilleure séquence thérapeutique chez les patients ayant un CBNPC avec mutation activatrice de l'EGFR ?

Initial EGFR-TKI is associated with a higher ORR and PFS as well as superior toxicity and QoL profiles as compared to chemotherapy. However, the lack of an OS benefit for firstline EGFR-TKI suggests that the best timing of treatment of EGFR-TKI is second-line, as a significant proportion of patients treated with initial EGFR-TKI could not have a chance to receive following chemotherapies. For the moment, it appears judicious to make a decision on a case by case basis, waiting for specific comparative studies.